In the early stages of development, gathering reliable information with a quick response time is of paramount importance. VIMTA offers a complete range of services dedicated to early phase drug candidate selection and development, where test item quantities, time to results and price are optimized for fast and robust decision making.
Our established in vitro / in vivo models help in effectively evaluating the efficacy of your molecule and establishing PK-PD relationship, while our customized approach helps our clients fast track the efficacy and safety testing to support lead identification & optimization. The routinely employed models can be fully integrated with histology, pathology, immunohistochemistry, flow cytometry, telemetric readouts and behavioural assay.
We offer various disease models such as
Pain and Inflammatory models
Metabolic Disorder Models
Our service offerings include
DMPK studies, often referred to as ADMET studies are critical in the drug discovery and development process as they help in determining the viability of a drug candidate. The selection of drug candidates with best ADMET properties enhances the probability of clinical success by helping the drug developers understand the safety and efficacy of the drug. Our objective is to design the studies that are necessary for your molecule in the most efficient and cost effective way.
VIMTA offers the complete range of ADMET studies which are critical for ensuring clinical success. We use in vitro human-based experimental system in combination with in vivo animal systems by using animal species relevant to humans, thus representing the best approach to assess these important drug-like properties before clinical trials. All in vitro and in vivo studies are performed under strict quality control, and we have experience of different administration routes in single or multiple dosing. Our in vitro ADME studies include
Drug – Drug Interaction studies
Metabolite Profiling Studies